NO20014192L - Fremgangsmåte ved ökning av benvolum ved å anvende ikke naturlig forekommende EP1-selektive agonister - Google Patents

Fremgangsmåte ved ökning av benvolum ved å anvende ikke naturlig forekommende EP1-selektive agonister

Info

Publication number
NO20014192L
NO20014192L NO20014192A NO20014192A NO20014192L NO 20014192 L NO20014192 L NO 20014192L NO 20014192 A NO20014192 A NO 20014192A NO 20014192 A NO20014192 A NO 20014192A NO 20014192 L NO20014192 L NO 20014192L
Authority
NO
Norway
Prior art keywords
naturally occurring
bone volume
increasing bone
selective agonists
selective
Prior art date
Application number
NO20014192A
Other languages
English (en)
Other versions
NO20014192D0 (no
Inventor
James Richard Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO20014192D0 publication Critical patent/NO20014192D0/no
Publication of NO20014192L publication Critical patent/NO20014192L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet fremgangsmåter for å øke benvolum omfattende administrasjonen av en ikke naturlig forekommende selektiv EP^agonist til et individ som har behov for slik behandling. Det er videre beskrevet fremgangsmåter for å behandle og forebygge benlidelser omfattende admini- strasjonen av en ikke naturlig forekommende selektiv EP^- agonist til et individ som har behov for slik behandling.
NO20014192A 1999-03-05 2001-08-29 Fremgangsmåte ved ökning av benvolum ved å anvende ikke naturlig forekommende EP1-selektive agonister NO20014192L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12306399P 1999-03-05 1999-03-05
PCT/US2000/005196 WO2000051585A2 (en) 1999-03-05 2000-03-01 Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume

Publications (2)

Publication Number Publication Date
NO20014192D0 NO20014192D0 (no) 2001-08-29
NO20014192L true NO20014192L (no) 2001-11-05

Family

ID=22406507

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014192A NO20014192L (no) 1999-03-05 2001-08-29 Fremgangsmåte ved ökning av benvolum ved å anvende ikke naturlig forekommende EP1-selektive agonister

Country Status (10)

Country Link
EP (1) EP1158969A2 (no)
JP (1) JP2002538105A (no)
AU (1) AU3711900A (no)
CA (1) CA2366755A1 (no)
CO (1) CO5150205A1 (no)
IL (1) IL145128A0 (no)
NO (1) NO20014192L (no)
NZ (1) NZ513828A (no)
PE (1) PE20001552A1 (no)
WO (1) WO2000051585A2 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118173A1 (ja) 2005-04-28 2006-11-09 Ono Pharmaceutical Co., Ltd. 経皮吸収製剤
EP2085088A4 (en) 2006-10-26 2012-08-29 Ono Pharmaceutical Co ADHESIVE PREPARATION
US20110038884A1 (en) 2008-04-28 2011-02-17 National University Co., Hamamatsu Univer. School Of Medicine Immunopotentiating agent comprising ep1 agonist
WO2011109729A2 (en) * 2010-03-05 2011-09-09 University Of Rochester Ep1 inhibition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3982016A (en) * 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
AU2146592A (en) * 1991-05-29 1993-01-08 Sepracor, Inc. Combination of nsaids and prostaglandins and uses therefor
WO1999012551A1 (en) * 1997-09-09 1999-03-18 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring fp selective agonists
JP2002527400A (ja) * 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド 骨形成刺激方法
WO2000051616A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives

Also Published As

Publication number Publication date
NO20014192D0 (no) 2001-08-29
EP1158969A2 (en) 2001-12-05
JP2002538105A (ja) 2002-11-12
CA2366755A1 (en) 2000-09-08
IL145128A0 (en) 2002-06-30
WO2000051585A3 (en) 2001-01-25
CO5150205A1 (es) 2002-04-29
AU3711900A (en) 2000-09-21
WO2000051585A2 (en) 2000-09-08
NZ513828A (en) 2001-09-28
PE20001552A1 (es) 2001-01-30

Similar Documents

Publication Publication Date Title
NO20001171L (no) FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister
TW366342B (en) The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
DE69616375T2 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
WO2000008015A3 (en) Fsh mimetics for the treatment of infertility
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
MY169308A (en) Treatment of tnf? related disorders
DE69827651D1 (de) Verwendung von tempol zur behandlung von essentiellem hochdruck
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
EP0950417A3 (en) Treatment of skeletal disorders
Tian et al. Rejuvenation of degenerative thymus by oral melatonin administration and the antagonistic action of melatonin against hydroxyl radical‐induced apoptosis of cultured thymocytes in mice
NO20052040L (no) Fremgangsmater og sammensetninger for behandling av autoimmune forstyrrelser ved anvendelse av clofarabine
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
SE9603725D0 (sv) New teatment
NO20014192L (no) Fremgangsmåte ved ökning av benvolum ved å anvende ikke naturlig forekommende EP1-selektive agonister
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
IT1274481B (it) Composizioni farmaceutiche per il trattamento della alcol-dipendenza
NO985573L (no) Veksthormonkomponent og ben-antiresorpsjonsmiddel ved syklisk (koherens-) behandling av osteoporose
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
EP1051993A3 (en) 5HT1 receptor agonists and either a COX-2 inhibitor or NSAID for the treatment of migraine
EP1064967A3 (en) 5HT1 receptor agonists, caffeine and either a COX-2 inhibitor or NSAID for the treatment of migraine
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
EP1051994A3 (en) 5HT1 receptor agonists and a COX-2 inhibitor for the treatment of migraine
NO985695L (no) Formulering og fremgangsmÕte for Õ behandle kongestiv hjerteinfarkt
NO20091111L (no) Anvendelse av R(+)-alfa-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidin-metanol for behandling av sovnforstyrrelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application